We are pleased to be collaborating with Penn and value the contributions of their scientists to this exciting field, said, Agios chief executive officer David Schenkein.
Chi Van Dang added, We look forward to working with Agios on this project and potentially other unrelated projects in the future.
The connection between cancer and metabolism has been the focus of scientists at Agios
, who were the first to identify the activity of IDH1 mutations and the production of the oncometabolite 2-HG in research published in Nature in 2009.
Past successful Flagship portfolio companies include: Accuri Cytometers (acquired by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by Eli Lilly), Agios
), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ: BGMD), Receptos (NASDAQ: RCPT), Tetraphase (NASDAQ: TTPH), and Morphotek (acquired by Eisai).
scientists discovered novel compounds that effectively increase activity of a cancer-associated isoform of pyruvate kinase (PKM2) in the glycolytic pathway, which is a conserved metabolic pathway that processes sugar to fuel cell growth.
DeVita joins Agios
after a highly productive career at Merck Research Laboratories in Rahway, NJ, where he was director of medicinal chemistry.
Michael Hui, founder and CEO of ChemPartner, said, "ChemPartner is pleased to build upon this existing collaboration and work closely with the experienced scientists at Agios
to develop new clinical compounds for oncology indications.
The important discovery by Agios
and the publication of the Nature article solidifies Agios
' leading role in cancer metabolism," Michael Hui, founder and CEO of ChemPartner commented.
Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, announced today that preclinical data from Agios
research were highlighted in two poster sessions and an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.
Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that is has secured $78 million in an oversubscribed Series C financing.
Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that Celgene Corporation (NASDAQ: CELG) and Agios
have agreed, ahead of schedule, to extend the initial period of exclusivity of the companies' April 2010 collaboration agreement from three to four years.
I am delighted to be able to contribute my expertise as the company moves these programs forward and to work with the impressive team Agios